Zydus Obtains USFDA Approval for Generic Version of Venlafaxine, Pregabalin



Zydus Lifesciences Ltd announced on Wednesday that it has received final approval from the US health regulator to market its generic version of venlafaxine extended-release tablets used to treat depression.

The company also said the United States Food and Drug Administration (USFDA) has granted final approval for pregabalin extended-release tablets used to treat pain caused by nerve damage due to diabetes or infection with shingles (herpes zoster).

USFDA approval for venlafaxine extended-release tablets is for 37.5 mg, 75 mg, 150 mg and 225 mg strengths, Zydus Lifesciences said in a regulatory filing.

Venlafaxine is used to treat depression, anxiety, panic attacks, and social anxiety disorder. It has annual sales of $46 million in the United States, the company said citing IQVIA MAT in July 2022.

Additionally, Zydus Lifesciences said final USFDA approval to market pregabalin extended-release tablets is in 82.5 mg, 165 mg, and 330 mg strengths. The drug has achieved annual sales of $3 million in the United States according to IQVIA MAT data from June 2022.

Both drugs will be manufactured at the group’s formulation manufacturing plant in Ahmedabad SEZ, he added.

(Only the title and image of this report may have been edited by Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always endeavored to provide up-to-date information and commentary on developments that matter to you and that have wider political and economic implications for the country and the world. Your constant encouragement and feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these challenging times stemming from Covid-19, we remain committed to keeping you informed and up-to-date with credible news, authoritative opinions and incisive commentary on relevant topical issues.
However, we have a request.

As we battle the economic impact of the pandemic, we need your support even more so that we can continue to bring you more great content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of bringing you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism we are committed to.

Support quality journalism and subscribe to Business Standard.

digital editor

About Margie Peters

Check Also

Lifestyle interventions can help pediatricians meet growing need for depression management in young people

With the increasing prevalence of depression in adolescents, screening requirements increasingly fall on pediatric primary …